About Incannex
Incannex is a company based in Melbourne (Australia) founded in 2015. The company has 9 employees. Incannex offers products and services including IHL-42X, IHL-675A, and PSX-001. Incannex operates in a competitive market with competitors including ATAI, COMPASS Pathways, MindMed, ZYUS Life Sciences and Beckley Psytech, among others.
- Headquarter Melbourne, Australia
- Employees 9
- Stage Public
- SectorsHealthcare
- Website incannex.com
- Social LinkedIn X
- Legal Name Incannex Healthcare Inc.
- Net Profit-$19.3 M (USD)58.83as on Jun 30, 2026
- EBITDA-$22.79 M (USD)3.21as on Jun 30, 2026
- Latest Funding Round$12.5M (USD), Post-IPO
Mar 2025
- Employee Count9
Products & Services of Incannex
Incannex offers a comprehensive portfolio of products and services, including IHL-42X, IHL-675A, and PSX-001.
Oral combination for treating obstructive sleep apnea symptoms.
Fixed-dose treatment targeting rheumatoid arthritis inflammation.
Synthetic psilocybin candidate for generalized anxiety disorder relief.
Funding Insights of Incannex
- Total Rounds 1
- Last Round Post-IPO — $12.5M
- First Round $12.5M
(Mar 2025)
All 1 funding rounds of Incannex with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2025 | $12.5M | Post-IPO | – | – | – |
People of Incannex
10 people are tracked at Incannex (7 in leadership, 3 in team); the tracked headcount is 9.
| Name | Role | Group |
|---|---|---|
Joel Latham | CEO & MD | Leadership |
Joseph Swan | Chief Financial Officer | Leadership |
Lekhram Changoer | Chief Technical Officer | Leadership |
Mark Bleackley | Chief Scientific Officer | Leadership |
Parisa Asvadi | Vice President, Research And Development | Leadership |
Lou Barbato | Chief Medical Officer | Leadership |
Natalie May | Head Of Clinical Operations | Leadership |
Pia Kroner | Associate Project Manager | Team |
George Williams Mbogo | Research & Regulatory Scientist | Team |
Kalani Scarrott | Financial Accountant | Team |
Complete people profiles for Incannex
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Incannex
Incannex is a publicly listed company on the NASDAQ with ticker symbol IXHL in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date04 Mar 2022
- Listed onNASDAQ: IXHL
- Listed entityIncannex Healthcare Inc.
- Exchange sectorHealth technology
Timeline of Incannex
3 dated milestones of Incannex across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Incannex is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $12.5M.
Competitors of Incannex
Incannex operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ATAI, COMPASS Pathways, MindMed, ZYUS Life Sciences and Beckley Psytech, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| atai.life | 2018 | Munich, Germany | $386.67M | – | A biopharmaceutical company accelerating innovative mental health treatments. | |
| compasspathways.com | 2016 | London, United Kingdom | $108.55M | 166 | Therapies for mental disorders, including psilocybin for depression, are developed. | |
| mindmed.co | 2019 | New York, United States | – | 74 | Psychedelic-based therapies for brain health disorders are developed. | |
| zyus.com | 2018 | Saskatoon, Canada | $19.5M | – | Cannabis-derived therapeutics for multiple indications are developed. | |
| beckleypsytech.com | 2019 | Oxford, United Kingdom | $152.62M | 1 | Developer of drugs for the treatment of neurological and psychiatric disorders | |
| cybin.com | 2002 | Toronto, Canada | – | – | Psychedelic therapeutics for psychiatric disorders are developed and provided. | |
| sanitygroup.com | 2011 | Berlin, Germany | $108.79M | – | Developer of cannabinoid-based pharmaceuticals and well-being products | |
| terraflos.com | 2021 | Uruguay | $8M | – | Medical cannabis products are provided based on GMP processes. | |
| psylo.bio | 2021 | Sydney, Australia | $14.18M | – | Psychedelic-derived therapeutics for mental illnesses are developed. |
Detailed competitors of Incannex
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Incannex
The website of Incannex (incannex.com) receives about 14.6K visits a month.
- Monthly visits14.6K
▼ 15% vs previous month
Websites whose visitors overlap most with Incannex. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| finimize.com | 100% | 272.1K | #186,141 | View details | |
| stockstotrade.com | 100% | 2.2M | #31,141 | View details | |
| rttnews.com | 40% | – | #203,816 | View details |
Latest news on Incannex
Complete news archive for Incannex
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Incannex
10 companies that operate in the same segment as Incannex (Cannabis Health Tech Ecosystem), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Cannabis products are provided to support consumer wellness and health. | 2013 | Smiths Falls, Ontario, Canada | – | USD 204.24 M | 960 | |
Online marketplace platform for cannabis traders | 2015 | New York, New York, United States | USD 195.4 M | – | – | |
Loyalty and marketing solutions for cannabis dispensaries are provided. | 2012 | West Palm Beach, Florida, United States | USD 25.79 M | USD 22.83 M | – | |
An online marketplace for cannabis products is operated. | 2017 | Bend, Oregon, United States | USD 603 M | – | 137 | |
Online platform for cannabis strains, reviews, and ratings | 2010 | Seattle, Washington, United States | USD 40.7 M | – | – | |
Provider of cannabis products, brands, and international business development investments | 2013 | Moncton, New Brunswick, Canada | – | USD 186.16 M | 898 | |
ERP software is offered via cloud platform for cannabis operations. | 2018 | Boston, Massachusetts, United States | – | USD 110.08 M | 313 | |
Online marketplace connecting licensed cannabis vendors and dispensaries | 2015 | Chicago, Illinois, United States | USD 22.57 M | – | – | |
Enterprise software is provided for cannabis dispensary management. | 2016 | Oakland, California, United States | USD 75.5 M | USD 148.97 K | 97 | |
Proprietary medical cannabis strains are developed and offered. | 2014 | Maryland Heights, Missouri, United States | USD 156 M | – | 557 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Incannex
Incannex was founded in 2015 and raised its 1st funding round 10 years after it was founded.
Incannex is headquartered in Melbourne, Australia. It is registered at Melbourne, Victoria, Australia.
Joel Latham is the current CEO of Incannex.
Incannex has 9 employees.
Incannex was founded in 2015 and is headquartered in Melbourne, Australia. As a clinical-stage pharmaceutical company, operations are centered on the advancement of medicinal cannabinoid compounds and psychedelic therapies. A portfolio of 28 FDA-compliant RD programs is managed, covering various therapeutic areas. Leadership is provided by CEO MD Joel Latham, with focus placed on regulatory-compliant drug development in the biotechnology sector.
Incannex's top competitors include MindMed, COMPASS Pathways and Beckley Psytech.
Incannex offers IHL-42X, IHL-675A, and PSX-001.
Yes, Incannex is publicly traded on NASDAQ under the ticker symbol IXHL.
Incannex operates through Incannex Healthcare Inc..